Unknown

Dataset Information

0

HBeAg seroconversion is associated with a more effective PD-L1 blockade during chronic hepatitis B infection.


ABSTRACT: Background & Aims:Current therapies for chronic hepatitis B virus (HBV) infection control viral replication but do not eliminate the risk of progression to hepatocellular carcinoma. HBV-specific CD8 T cells are necessary for viral control, but they are rare and exhausted during chronic infection. Preclinical studies have shown that blockade of the PD-1:PD-L1 axis can restore HBV-specific T cell functionality. The aim of this study was to analyze how the clinical and treatment status of patients impacts the ability of HBV-specific T cells to respond to PD-L1 blockade. Methods:Expression patterns of the PD-1:PD-L1/PD-L2 axis were analyzed in healthy donors and chronically infected patients in different clinical phases of disease. A functional assay was performed to quantify baseline HBV-specific T cell responses in chronically infected patients. Baseline responses were then compared to those attained in the presence of an anti-PD-L1 monoclonal antibody (MEDI2790). Results:Chronically infected patients were characterized by the upregulation of PD-1 within the T cell compartment and a concomitant upregulation of PD-L1 on myeloid dendritic cells. The upregulation was maximal in HBV e antigen (HBeAg)-positive patients but persisted after HBeAg negativization and was not restored by long-term treatment. HBV reactivity, measured as frequency of HBV-specific T cells, was significantly higher in HBeAg-negative patients with lower HBV DNA levels, independently of HBV surface antigen or alanine aminotransferase levels. Anti-PD-L1 blockade with MEDI2790 increased both the number of IFN-?-producing T cells and the amount of IFN-? produced per cell in 97% of patients with detectable HBV reactivity, independently of patients' clinical or treatment status. Conclusion:Patients with lower levels of HBV DNA and the absence of HBeAg have more intact HBV-specific T cell immunity and may benefit the most from PD-L1 blockade as a monotherapy. Lay summary:Hepatitis B virus (HBV)-specific T cell responses during chronic infection are weak due to the upregulation of inhibitor molecules on the immune cells. In this study we show that the inhibitory PD-1:PD-L1 axis is upregulated during chronic HBV infection and successful antiretroviral therapy does not restore normal levels of PD-1 and PD-L1 expression. However, in HBV e antigen-negative patients, treatment with an anti-PD-L1 antibody can increase the functionality of HBV-specific T cell responses by an average of 2-fold and is a promising new therapy for patients with chronic HBV infection.

SUBMITTER: Ferrando-Martinez S 

PROVIDER: S-EPMC7001560 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

HBeAg seroconversion is associated with a more effective PD-L1 blockade during chronic hepatitis B infection.

Ferrando-Martinez Sara S   Huang Kelly K   Bennett Angie Snell AS   Sterba Patricia P   Yu Li L   Suzich JoAnn A JA   Janssen Harry L A HLA   Robbins Scott H SH  

JHEP reports : innovation in hepatology 20190628 3


<h4>Background & aims</h4>Current therapies for chronic hepatitis B virus (HBV) infection control viral replication but do not eliminate the risk of progression to hepatocellular carcinoma. HBV-specific CD8 T cells are necessary for viral control, but they are rare and exhausted during chronic infection. Preclinical studies have shown that blockade of the PD-1:PD-L1 axis can restore HBV-specific T cell functionality. The aim of this study was to analyze how the clinical and treatment status of p  ...[more]

Similar Datasets

| S-EPMC4230803 | biostudies-other
| S-EPMC3371426 | biostudies-literature
| S-EPMC6685986 | biostudies-literature
| S-EPMC6081408 | biostudies-literature
| S-EPMC10836741 | biostudies-literature
| S-EPMC5249087 | biostudies-literature
| S-EPMC7270402 | biostudies-literature
| S-EPMC6159957 | biostudies-literature
| S-EPMC5994550 | biostudies-literature
| S-EPMC4468690 | biostudies-literature